Avadel Pharmaceuticals plc

NasdaqGM AVDL

Avadel Pharmaceuticals plc Free Cash Flow for the year ending December 31, 2023: USD -128.51 M

Avadel Pharmaceuticals plc Free Cash Flow is USD -128.51 M for the year ending December 31, 2023, a -80.95% change year over year. Free cash flow is the amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.

Avadel Pharmaceuticals plc Free Cash Flow for the year ending December 31, 2022 was USD -71.02 M, a 8.17% change year over year.
Avadel Pharmaceuticals plc Free Cash Flow for the year ending December 31, 2021 was USD -77.34 M, a -58.37% change year over year.
Avadel Pharmaceuticals plc Free Cash Flow for the year ending December 31, 2020 was USD -48.83 M, a -27.32% change year over year.
Avadel Pharmaceuticals plc Free Cash Flow for the year ending December 31, 2019 was USD -38.35 M, a 62.72% change year over year.

Key data

Date	Free Cash Flow	Operating Cash Flow	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities

NasdaqGM: AVDL

Avadel Pharmaceuticals plc

CEO	Mr. Gregory J. Divis Jr.
IPO Date	June 7, 1996
Location	Ireland
Headquarters	10 Earlsfort Terrace
Employees	154
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

Key trends

Past 5 years